Somatostatin-28 modulates prepulse inhibition of the acoustic startle response, reward processes and spontaneous locomotor activity in rats

Neuropeptides

Volumn 44, Issue 5, 2010, Pages 421-429

  Semenova, Svetlana ^a   Hoyer, Daniel ^b   Geyer, Mark A ^a   Markou, Athina ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Anhedonia; Intracranial self stimulation; Reward thresholds; Schizophrenia; Sensorimotor gating; SRA 880

Indexed keywords

HORMONE RECEPTOR BLOCKING AGENT; SOMATOSTATIN 28; SRA 880; UNCLASSIFIED DRUG;

ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; EXPLORATORY BEHAVIOR; HABITUATION; LOCOMOTION; MALE; MOTOR PERFORMANCE; NEUROTRANSMISSION; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; REWARD; SCHIZOPHRENIA; SOMATOSENSORY SYSTEM; STARTLE REFLEX;

ACOUSTIC STIMULATION; ANALYSIS OF VARIANCE; ANIMALS; CATHETERS, INDWELLING; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR; REACTION TIME; REWARD; SENSORY GATING; SOMATOSTATIN-28; STARTLE REACTION;

RATTUS;

EID: 77956189063     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2010.04.008     Document Type: Article

References (83)

1. Allen J.P., Hathway G.J., Clarke N.J., Jowett M.I., Topps S., Kendrick K.M., Humphrey P.P., Wilkinson L.S., Emson P.C. Somatostatin receptor 2 knockout/lacZ knockin mice show impaired motor coordination and reveal sites of somatostatin action within the striatum. Eur. J. Neurosci. 2003, 17:1881-1895.
2. American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders, fourth ed. American Psychiatric Press, Washington, DC.
3. Balazs M., Schwarzberg H., Telegdy G. Effects of somatostatin on self-stimulation behaviour in rats pretreated with a receptor blocker. Eur. J. Pharmacol. 1988, 149:141-144.
4. Baldo B.A., Jain K., Veraldi L., Koob G.F., Markou A. A dopamine D1 agonist elevates self-stimulation thresholds: comparison to other dopamine-selective drugs. Pharmacol. Biochem. Behav. 1999, 62:659-672.
5. Bassareo V., De Luca M.A., Di Chiara G. Differential impact of pavlovian drug conditioned stimuli on in vivo dopamine transmission in the rat accumbens shell and core and in the prefrontal cortex. Psychopharmacology (Berl) 2007, 191:689-703.
6. Bissette G. Effects of sertraline on regional neuropeptide concentrations in olfactory bulbectomized rats. Pharmacol. Biochem. Behav. 2001, 69:269-281.
7. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 2001, 156:234-258.
8. Brownstein M., Arimura A., Sato H., Schally A.V., Kizer J.S. The regional distribution of somatostatin in the rat brain. Endocrinology 1975, 96:1456-1461.
9. Bruijnzeel A.W., Markou A. Decreased sensitivity to the effects of dopamine D1-like, but not D2-like, receptor antagonism in the posterior hypothalamic region/anterior ventral tegmental area on brain reward function during chronic exposure to nicotine in rats. Brain Res. 2005, 1058:91-100.
10. David H.N., Ansseau M., Abraini J.H. Dopamine-glutamate reciprocal modulation of release and motor responses in the rat caudate-putamen and nucleus accumbens of " intact" animals. Brain Res. Brain Res. Rev. 2005, 50:336-360.
11. Davis M., Falls W.A., Campeau S., Kim M. Fear-potentiated startle: a neural and pharmacological analysis. Behav. Brain Res. 1993, 58:175-198.
12. 1 receptors are autoreceptors and do not affect seizures in rats. Neuroreport 2010, 21:254-258.
13. Deutch A.Y. Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease. J. Neural Transm. Gen. Sect. 1993, 91:197-221.
14. Deutch A.Y., Cameron D.S. Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience 1992, 46:49-56.
15. Engin E., Stellbrink J., Treit D., Dickson C.T. Anxiolytic and antidepressant effects of intracerebroventricularly administered somatostatin: behavioral and neurophysiological evidence. Neuroscience 2008, 157:666-676.
16. Epelbaum J., Guillou J.L., Gastambide F., Hoyer D., Duron E., Viollet C. Somatostatin, Alzheimer's disease and cognition: an old story coming of age?. Prog. Neurobiol. 2009, 89:153-161.
17. Fehlmann D., Langenegger D., Schuepbach E., Siehler S., Feuerbach D., Hoyer D. Distribution and characterisation of somatostatin receptor mRNA and binding sites in the brain and periphery. J. Physiol. Paris 2000, 94:265-281.
18. Feifel D., Minor K.L. Cysteamine blocks amphetamine-induced deficits in sensorimotor gating. Pharmacol. Biochem. Behav. 1997, 58:689-693.
19. Fendt M., Koch M., Schnitzler H.U. Somatostatin in the pontine reticular formation modulates fear potentiation of the acoustic startle response: an anatomical, electrophysiological, and behavioral study. J. Neurosci. 1996, 16:3097-3103.
20. Geyer M.A. Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia?. Dialogues Clin. Neurosci. 2006, 8:9-16.
21. Geyer M.A., Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:1071-1079.
22. Geyer M.A., Russo P.V., Masten V.L. Multivariate assessment of locomotor behavior: pharmacological and behavioral analyses. Pharmacol. Biochem. Behav. 1986, 25:277-288.
23. Geyer M.A., Swerdlow N.R., Mansbach R.S., Braff D.L. Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res. Bull. 1990, 25:485-498.
24. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001, 156:117-154.
25. Geyer M.A., McIlwain K.L., Paylor R. Mouse genetic models for prepulse inhibition: an early review. Mol. Psychiatry 2002, 7:1039-1053.
26. Hathway G.J., Emson P.C., Humphrey P.P., Kendrick K.M. Somatostatin potently stimulates in vivo striatal dopamine and γ-aminobutyric acid release by a glutamate-dependent action. J. Neurochem. 1998, 70:1740-1749.
27. 2 receptors mediate striatal dopamine release. Br. J. Pharmacol. 1999, 128:1346-1352.
28. Holmes A., Wrenn C.C., Harris A.P., Thayer K.E., Crawley J.N. Behavioral profiles of inbred strains on novel olfactory, spatial and emotional tests for reference memory in mice. Genes Brain Behav. 2002, 1:55-69.
29. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr. Bull. 2009, 35:549-562.
30. Hoyer D., Bell G.I., Berelowitz M., Epelbaum J., Feniuk W., Humphrey P.P., O'Carroll A.M., Patel Y.C., Schonbrunn A., Taylor J.E., et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol. Sci. 1995, 16:86-88.
31. 1 receptor antagonist. Neurosci. Lett. 2004, 361:132-135.
32. Ikeda H., Kotani A., Koshikawa N., Cools A.R. Somatostatin receptors in the nucleus accumbens modulate dopamine-dependent but not acetylcholine-dependent turning behaviour of rats. Neuroscience 2009, 159:974-981.
33. Kenny P.J., Koob G.F., Markou A. Conditioned facilitation of brain reward function after repeated cocaine administration. Behav. Neurosci. 2003, 117:1103-1107.
34. Kluge C., Stoppel C., Szinyei C., Stork O., Pape H.C. Role of the somatostatin system in contextual fear memory and hippocampal synaptic plasticity. Learn Mem. 2008, 15:252-260.
35. Koob G.F., Volkow N.D. Neurocircuitry of addiction. Neuropsychopharmacology 2010, 35:217-238.
36. Kornetsky C., Esposito R.U., McLean S., Jacobson J.O. Intracranial self-stimulation thresholds: a model for the hedonic effects of drugs of abuse. Arch. Gen. Psychiatry 1979, 36:289-292.
37. Kungel M., Koch M., Friauf E. Cysteamine impairs the development of the acoustic startle response in rats: possible role of somatostatin. Neurosci. Lett. 1996, 202:181-184.
38. Lee N., Radke J.M., Vincent S.R. Intra-cerebral cysteamine infusions attenuate the motor response to dopaminergic agonists. Behav. Brain Res. 1988, 29:179-183.
39. Lin D., Koob G.F., Markou A. Time-dependent alterations in ICSS thresholds associated with repeated amphetamine administrations. Pharmacol. Biochem. Behav. 2000, 65:407-417.
40. Mague S.D., Andersen S.L., Carlezon W.A. Early developmental exposure to methylphenidate reduces cocaine-induced potentiation of brain stimulation reward in rats. Biol. Psychiatry 2005, 57:120-125.
41. Mansbach R.S., Geyer M.A., Braff D.L. Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology (Berl) 1988, 94:507-514.
42. Marazioti A., Kastellakis A., Antoniou K., Papasava D., Thermos K. Somatostatin receptors in the ventral pallidum/substantia innominata modulate rat locomotor activity. Psychopharmacology (Berl) 2005, 181:319-326.
43. Marazioti A., Pitychoutis P.M., Papadopoulou-Daifoti Z., Spyraki C., Thermos K. Activation of somatostatin receptors in the globus pallidus increases rat locomotor activity and dopamine release in the striatum. Psychopharmacology (Berl) 2008, 201:413-422.
44. Markou A., Kenny P.J. Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories. Neurotox. Res. 2002, 4:297-313.
45. Markou A., Koob G.F. Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology 1991, 4:17-26.
46. Markou A., Koob G.F. Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol. Behav. 1992, 51:111-119.
47. Martin-Iverson M.T., Radke J.M., Vincent S.R. The effects of cysteamine on dopamine-mediated behaviors: evidence for dopamine-somatostatin interactions in the striatum. Pharmacol. Biochem. Behav. 1986, 24:1707-1714.
48. Olias G., Viollet C., Kusserow H., Epelbaum J., Meyerhof W. Regulation and function of somatostatin receptors. J. Neurochem. 2004, 89:1057-1091.
49. Pallis E., Thermos K., Spyraki C. Chronic desipramine treatment selectively potentiates somatostatin-induced dopamine release in the nucleus accumbens. Eur. J. Neurosci. 2001, 14:763-767.
50. Pallis E., Vasilaki A., Fehlmann D., Kastellakis A., Hoyer D., Spyraki C., Thermos K. Antidepressants influence somatostatin levels and receptor pharmacology in brain. Neuropsychopharmacology 2009, 34:952-963.
51. Patel Y.C. Somatostatin and its receptor family. Front Neuroendocrinol. 1999, 20:157-198.
52. Paterson N.E., Markou A. Animal models and treatments for addiction and depression co-morbidity. Neurotox. Res. 2007, 11:1-32.
53. Pellegrino L., Pellegrino A., Cushman A. A Stereotaxic Atlas of the Rat Brain 1986, Plenum Press, New York. second ed.
54. Pontieri F.E., Tanda G., Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the " shell" as compared with the " core" of the rat nucleus accumbens. Proc. Natl. Acad. Sci. USA 1995, 92:12304-12308.
55. Rakovska A., Kiss J.P., Raichev P., Lazarova M., Kalfin R., Milenov K. Somatostatin stimulates striatal acetylcholine release by glutamatergic receptors: an in vivo microdialysis study. Neurochem. Int. 2002, 40:269-275.
56. Rakovska A., Javitt D., Raichev P., Ang R., Balla A., Aspromonte J., Vizi S. Physiological release of striatal acetylcholine (in vivo): effect of somatostatin on dopaminergic-cholinergic interaction. Brain Res. Bull. 2003, 61:529-536.
57. Ralph R.J., Caine S.B. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice. J. Pharmacol. Exp. Ther. 2005, 312:733-741.
58. Raynor K., Lucki I., Reisine T. Somatostatin receptors in the nucleus accumbens selectively mediate the stimulatory effect of somatostatin on locomotor activity in rats. J. Pharmacol. Exp. Ther. 1993, 265:67-73.
59. Rubinow D.R. Cerebrospinal fluid somatostatin and psychiatric illness. Biol. Psychiatry 1986, 21:341-365.
60. Rubinow D.R., Gold P.W., Post R.M., Ballenger J.C. CSF somatostatin in affective illness and normal volunteers. Prog. Neuropsychopharmacol. Biol. Psychiatry 1985, 9:393-400.
61. Sagar S.M., Landry D., Millard W.J., Badger T.M., Arnold M.A., Martin J.B. Depletion of somatostatin-like immunoreactivity in the rat central nervous system by cysteamine. J. Neurosci. 1982, 2:225-231.
62. Santis S., Kastellakis A., Kotzamani D., Pitarokoili K., Kokona D., Thermos K. Somatostatin increases rat locomotor activity by activating sst(2) and sst(4) receptors in the striatum and via glutamatergic involvement. Naunyn Schmiedebergs Arch. Pharmacol. 2009, 379:181-189.
63. Semenova S., Markou A. Clozapine treatment attenuated somatic and affective signs of nicotine and amphetamine withdrawal in subsets of rats exhibiting hyposensitivity to the initial effects of clozapine. Biol. Psychiatry 2003, 54:1249-1264.
64. Siehler S., Nunn C., Hannon J., Feuerbach D., Hoyer D. Pharmacological profile of somatostatin and cortistatin receptors. Mol. Cell Endocrinol. 2008, 286:26-34.
65. Spanagel R., Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci. 1999, 22:521-527.
66. Swerdlow N.R., Geyer M.A. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr. Bull. 1998, 24:285-301.
67. Tashev R., Belcheva S., Milenov K., Belcheva I. Behavioral effects of somatostatin microinjected into caudate putamen. Neuropeptides 2001, 35:271-275.
68. Thermos K., Radke J., Kastellakis A., Anagnostakis Y., Spyraki C. Dopamine-somatostatin interactions in the rat striatum: an in vivo microdialysis study. Synapse 1996, 22:209-216.
69. 1 receptor: an autoreceptor for somatostatin in brain and retina?. Pharmacol. Ther. 2006, 110:455-464.
70. 1) modulates the release of somatostatin in the nucleus accumbens of the rat. Neuropharmacology 2004, 47:612-618.
71. Vecsei L., Klivenyi P. Somatostatin and Alzheimer's disease. Arch. Gerontol. Geriatr. 1995, 21:35-41.
72. Vecsei L., Widerlov E. Brain and CSF somatostatin concentrations in patients with psychiatric or neurological illness. An overview. Acta Psychiatr. Scand. 1988, 78:657-667.
73. Vecsei L., Widerlov E. Effects of intracerebroventricularly administered somatostatin on passive avoidance, shuttle-box behaviour and open-field activity in rats. Neuropeptides 1988, 12:237-242.
74. Vecsei L., Widerlov E. Effects of somatostatin-28 and some of its fragments and analogs on open-field behavior, barrel rotation, and shuttle box learning in rats. Psychoneuroendocrinology 1990, 15:139-145.
75. Vecsei L., Schwarzberg H., Telegdy G. Comparative studies with linear and cyclic somatostatin on the self-stimulation of rats. Acta Physiol. Acad. Sci. Hung. 1982, 60:165-168.
76. Vecsei L., Schwarzberg H., Telegdy G. The effect of somatostatin on self-stimulation behavior in atropine- and methysergide-pretreated rats. Eur. J. Pharmacol. 1983, 91:89-93.
77. Vecsei L., Kiraly C., Bollok I., Nagy A., Varga J., Penke B., Telegdy G. Comparative studies with somatostatin and cysteamine in different behavioral tests on rats. Pharmacol. Biochem. Behav. 1984, 21:833-837.
78. Vecsei L., Ekman R., Alling C., Widerlov E. Influence of cysteamine and cysteine on open-field behaviour, and on brain concentrations of catecholamines, somatostatin, neuropeptide Y, and corticotropin releasing hormone in the rat. J. Neural Transm. Gen. Sect. 1989, 78:209-220.
79. Vincent S.R., Johansson O. Striatal neurons containing both somatostatin- and avian pancreatic polypeptide (APP)-like immunoreactivities and NADPH-diaphorase activity: a light and electron microscopic study. J. Comp. Neurol. 1983, 217:264-270.
80. 2 somatostatin receptor in locomotor, exploratory activity and emotional reactivity in mice. Eur. J. Neurosci. 2000, 12:3761-3770.
81. Viollet C., Lepousez G., Loudes C., Videau C., Simon A., Epelbaum J. Somatostatinergic systems in brain: networks and functions. Mol. Cell Endocrinol. 2008, 286:75-87.
82. Vlachou, S., Markou, A., 2010. Intracranial self-stimulation: the use of the intracranial self-stimulation procedure in the investigation of reward and motivational processes: effects of drugs of abuse. In: Olmstead, M.C. (Ed.), Animal Models of Drug Addiction. Human Press Inc., in press.
83. Zeyda T., Diehl N., Paylor R., Brennan M.B., Hochgeschwender U. Impairment in motor learning of somatostatin null mutant mice. Brain Res. 2001, 906:107-114.